Implications of vancomycin-resistant Staphylococcus aureus

Journal of Hospital Infection

Volumn 43, Issue SUPPL. 1, 1999, Pages

  Tenover, F C ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Staphylococci; Vancomycin

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; METICILLIN; OXACILLIN; PENICILLIN DERIVATIVE; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CONFERENCE PAPER; HAND WASHING; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

FORECASTING; HUMANS; POPULATION SURVEILLANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 0033389160     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-6701(99)90060-9     Document Type: Article

References (23)

1. Cunha BA. Vancomycin. Med Clinics North America 1996; 79: 817-831.
2. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemotherapy 1997; 40: 135-136.
3. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR 1997; 46: 765-766.
4. Ploy MC, Grélaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.
5. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP. Vancomycin-resistant Staphylococcus aureus. Lancet 1998; 351: 602.
6. Hirmatsu K. Vancomycin resistance in staphylococci. Drug Resistance Updates 1998; 1: 135-150.
7. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed., vol. 17, No. 2. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa. 1997.
8. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 6th edition, vol. 17, No. 1. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa. 1997.
9. Goldstein F, Soussy C-J, Thabaut A. Report of the Comité de l'Antibiogramme de la Société Française de Microbiologie. Definition of the clinical antibacterial spectrum of activity. Clin Microbiol Infect 1996; 2: S40-S49.
10. Working Party of the British Society for Antimicrobial Chemotherapy. Breakpoints in in-vitro antibiotic susceptibility testing. J Antimicrob Chemother 1988; 21: 701-710.
11. Hiramatsu K, Aritaka N, Hanaki S et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-1673.
12. Tenover FC, Lancaster MV, Hill BC et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-1027.
13. Fitch L, Johnson AP. Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 1998; 41: 578.
14. Lye W, Leong SO, Lee EJC. Methicillin-resistant Staphylococcus aureus nasal carriage and infections in CAPD. Kidney Int 1993; 43: 1357-1362.
15. Kluytmans J, van Belkum A, Verbrugh N. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10: 505-520.
16. Zimakoff J, Pederseon FB, Bergen L et al. Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis centers in Denmark. J Hosp Infect 1996; 33: 289-300.
17. Panlilio AL, Dulver DH, Gaynes RP et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992; 13: 582-586.
18. Barett SP, Mummery RV, Chattopadhyay B. Trying to control MRSA causes more problems than it solves. J Hosp Infect 1998; 39: 85-93.
19. Irish D, Eltringham I, Teall A et al. Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin. J Hosp Infect 1998; 39: 19-26.
20. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1995; 44 (no. RR-12).
21. Centers for Disease Control and Prevention. Interim guideline for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR 1997; 46: 626-628, 635-636.
22. Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fiuoroquinolone (Trovafloxacin), and dalfopristinquinupristine against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996; 40: 2428-2430.
23. Noble WC, Varani Z, Cree RGA. Co-transfer of vancomycin and other resistant genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Letters 1992; 93: 195-198.